Modi 1
Alternative Names: Modi-1; Modi-1vLatest Information Update: 28 Jan 2025
At a glance
- Originator Scancell
- Class Antineoplastics; Cancer vaccines; Conjugate vaccines; Immunotherapies; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Head and neck cancer; Ovarian cancer; Renal cancer; Triple negative breast cancer
Most Recent Events
- 16 Jan 2025 Scancell Holdings has patent protection for Moditope® immunotherapy platform in USA
- 16 Jan 2025 Efficacy data from the phase I/II Modify trial in Renal cancer, Ovarian cancer, Head and neck cancer and Triple negative Breast cancer released by Scancell
- 30 Jan 2024 Updated efficacy and adverse events data from the phase I/II Modify trial in Renal cancer, Ovarian cancer, Head and neck cancer and Triple negative Breast cancer released by Scancell